281 related articles for article (PubMed ID: 32807174)
1. Angiotensin AT
Rivas-Santisteban R; Rodriguez-Perez AI; Muñoz A; Reyes-Resina I; Labandeira-García JL; Navarro G; Franco R
J Neuroinflammation; 2020 Aug; 17(1):243. PubMed ID: 32807174
[TBL] [Abstract][Full Text] [Related]
2. Novel Interactions Involving the Mas Receptor Show Potential of the Renin-Angiotensin system in the Regulation of Microglia Activation: Altered Expression in Parkinsonism and Dyskinesia.
Rivas-Santisteban R; Lillo J; Muñoz A; Rodríguez-Pérez AI; Labandeira-García JL; Navarro G; Franco R
Neurotherapeutics; 2021 Apr; 18(2):998-1016. PubMed ID: 33474655
[TBL] [Abstract][Full Text] [Related]
3. Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease.
Villar-Cheda B; Rodríguez-Pallares J; Valenzuela R; Muñoz A; Guerra MJ; Baltatu OC; Labandeira-Garcia JL
Eur J Neurosci; 2010 Nov; 32(10):1695-706. PubMed ID: 20964730
[TBL] [Abstract][Full Text] [Related]
4. The cannabinoid CB
Rivas-Santisteban R; Lillo J; Raïch I; Muñoz A; Lillo A; Rodríguez-Pérez AI; Labandeira-García JL; Navarro G; Franco R
Exp Neurol; 2023 Apr; 362():114319. PubMed ID: 36632949
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D2 and angiotensin II type 1 receptors form functional heteromers in rat striatum.
Martínez-Pinilla E; Rodríguez-Pérez AI; Navarro G; Aguinaga D; Moreno E; Lanciego JL; Labandeira-García JL; Franco R
Biochem Pharmacol; 2015 Jul; 96(2):131-42. PubMed ID: 25986885
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin type 2 receptors: Role in aging and neuroinflammation in the substantia nigra.
Rodriguez-Perez AI; Garrido-Gil P; Pedrosa MA; Garcia-Garrote M; Valenzuela R; Navarro G; Franco R; Labandeira-Garcia JL
Brain Behav Immun; 2020 Jul; 87():256-271. PubMed ID: 31863823
[TBL] [Abstract][Full Text] [Related]
7. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
Muñoz A; Garrido-Gil P; Dominguez-Meijide A; Labandeira-Garcia JL
Exp Neurol; 2014 Nov; 261():720-32. PubMed ID: 25160895
[TBL] [Abstract][Full Text] [Related]
9. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB
Navarro G; Borroto-Escuela D; Angelats E; Etayo Í; Reyes-Resina I; Pulido-Salgado M; Rodríguez-Pérez AI; Canela EI; Saura J; Lanciego JL; Labandeira-García JL; Saura CA; Fuxe K; Franco R
Brain Behav Immun; 2018 Jan; 67():139-151. PubMed ID: 28843453
[TBL] [Abstract][Full Text] [Related]
10. Aging-related dysregulation of dopamine and angiotensin receptor interaction.
Villar-Cheda B; Dominguez-Meijide A; Valenzuela R; Granado N; Moratalla R; Labandeira-Garcia JL
Neurobiol Aging; 2014 Jul; 35(7):1726-38. PubMed ID: 24529758
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration.
Valenzuela R; Costa-Besada MA; Iglesias-Gonzalez J; Perez-Costas E; Villar-Cheda B; Garrido-Gil P; Melendez-Ferro M; Soto-Otero R; Lanciego JL; Henrion D; Franco R; Labandeira-Garcia JL
Cell Death Dis; 2016 Oct; 7(10):e2427. PubMed ID: 27763643
[TBL] [Abstract][Full Text] [Related]
12. Paracrine and Intracrine Angiotensin 1-7/Mas Receptor Axis in the Substantia Nigra of Rodents, Monkeys, and Humans.
Costa-Besada MA; Valenzuela R; Garrido-Gil P; Villar-Cheda B; Parga JA; Lanciego JL; Labandeira-Garcia JL
Mol Neurobiol; 2018 Jul; 55(7):5847-5867. PubMed ID: 29086247
[TBL] [Abstract][Full Text] [Related]
13. Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
Brugnoli A; Pisanò CA; Morari M
Neurobiol Dis; 2020 Oct; 144():105044. PubMed ID: 32798726
[TBL] [Abstract][Full Text] [Related]
14. Cerebral ischemia induced inflammatory response and altered glutaminergic function mediated through brain AT
Justin A; Divakar S; Ramanathan M
Biomed Pharmacother; 2018 Jun; 102():947-958. PubMed ID: 29710550
[TBL] [Abstract][Full Text] [Related]
15. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
Giorgi M; D'Angelo V; Esposito Z; Nuccetelli V; Sorge R; Martorana A; Stefani A; Bernardi G; Sancesario G
Eur J Neurosci; 2008 Sep; 28(5):941-50. PubMed ID: 18717735
[TBL] [Abstract][Full Text] [Related]
16. Type 1 angiotensin receptor (AT1-R)-mediated decrease in type 2 angiotensin receptor mRNA level is dependent on Gq and extracellular signal-regulated kinase 1//2 in AT1-R-transfected PC12 cells.
Saito M; Shinohara Y; Sasaki H; Netsu Y; Yoshida M; Nakahata N
J Neuroendocrinol; 2008 Mar; 20(3):299-308. PubMed ID: 18208547
[TBL] [Abstract][Full Text] [Related]
17. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
[TBL] [Abstract][Full Text] [Related]
18. Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia.
Brugnoli A; Napolitano F; Usiello A; Morari M
Neurobiol Dis; 2016 Jan; 85():155-163. PubMed ID: 26522958
[TBL] [Abstract][Full Text] [Related]
19. The role of the brain renin-angiotensin system in Parkinson´s disease.
Labandeira-Garcia JL; Labandeira CM; Guerra MJ; Rodriguez-Perez AI
Transl Neurodegener; 2024 Apr; 13(1):22. PubMed ID: 38622720
[TBL] [Abstract][Full Text] [Related]
20. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
